InvestorsHub Logo
Followers 23
Posts 1725
Boards Moderated 0
Alias Born 09/03/2015

Re: namtae post# 13278

Saturday, 11/11/2017 1:18:23 PM

Saturday, November 11, 2017 1:18:23 PM

Post# of 21373
You've got to be kidding me?? I've been a finance manager and worked with loan officers and the only way you can get business credit is having a revenue generating business. A clinical stage biopharma has no way to produce revenue and therefore has no way to pay back a loan and build credit. What bank is going to lend money to a company with income?This is the struggle that almost every clinical stage company has to endure. They need venture capital, private offerings, or what you refer to as toxic financing to conduct business. Toxic financiers are the only ones willing to take on the risk of lending money to non revenue generating biopharma's.

The fact that they were able to obtain as much VC money and donations for the past 10+ years is pretty telling. Most small clinical stage biopharma's are lucky if they can even raise $1m. Oncolix has raised $15m-$20m.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.